Endothelin Receptor Antagonists in Kidney Protection for Diabetic Kidney Disease and Beyond?

Overview

Journal Nephrology (Carlton)

Specialty Nephrology

Date 2022 Nov 9

PMID 36350038

Authors

Edmund Y M Chung

Sunil V Badve

Hiddo J L Heerspink

Muh Geot Wong

Affiliations

Soon will be listed here.

Abstract

The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global prevalence of diabetes mellitus and hypertension. While renin angiotensin system inhibitors and sodium-glucose cotransporter two inhibitors are the management cornerstone for reducing kidney and cardiovascular complications in patients with diabetic and non-diabetic kidney disease (DKD), they are partially effective and further treatments are needed to prevent the progression to kidney failure. Endothelin receptor antagonism represent a potential additional therapeutic option due to its beneficial effect on pathophysiological processes involved in progressive kidney disease including proteinuria, which are independently associated with progression of kidney disease. This review discusses the biological mechanisms of endothelin receptor antagonists (ERA) in kidney protection, the efficacy and safety of ERA in randomised controlled trials reporting on kidney outcomes, and its potential future use in both diabetic and non-DKDs.

Citing Articles

Impact of hospital-based early detection on management in chronic kidney disease: the CKD Stewardship study (CKD-S) - protocol for a prospective, multicentre, observational cohort study.

Wynter L, Smyth B, Saunders J, Moroney C, Gorringe L, Turner K BMJ Open. 2025; 15(3):e094554.

PMID: 40044204 PMC: 11883606. DOI: 10.1136/bmjopen-2024-094554.

Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.

Alicic R, Neumiller J, Tuttle K Nephrol Dial Transplant. 2025; 40(Supplement_1):i3-i17.

PMID: 39907543 PMC: 11795665. DOI: 10.1093/ndt/gfae212.

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Moedt E, Wasehuus V, Heerspink H Nephrol Dial Transplant. 2025; 40(Supplement_1):i37-i46.

PMID: 39907539 PMC: 11795649. DOI: 10.1093/ndt/gfae214.

Drug repurposing for glomerular diseases: an underutilized resource.

Ng M, Kaur G, Francis R, Hawley C, Johnson D Nat Rev Nephrol. 2024; 20(11):707-721.

PMID: 39085415 DOI: 10.1038/s41581-024-00864-8.

Combination therapy for kidney disease in people with diabetes mellitus.

van Raalte D, Bjornstad P, Cherney D, de Boer I, Fioretto P, Gordin D Nat Rev Nephrol. 2024; 20(7):433-446.

PMID: 38570632 DOI: 10.1038/s41581-024-00827-z.

References

Seibold J, Denton C, Furst D, Guillevin L, Rubin L, Wells A . Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010; 62(7):2101-8. DOI: 10.1002/art.27466. View

Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T . Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. BMC Clin Pharmacol. 2011; 11:3. PMC: 3070638. DOI: 10.1186/1472-6904-11-3. View

Hoekman J, Lambers Heerspink H, Viberti G, Green D, Mann J, de Zeeuw D . Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clin J Am Soc Nephrol. 2014; 9(3):490-8. PMC: 3944766. DOI: 10.2215/CJN.07040713. View

Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, Lopez-Armada M, Plaza J . Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension. 1996; 27(4):885-92. DOI: 10.1161/01.hyp.27.4.885. View

Dingemanse J, Clozel M, van Giersbergen P . Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol. 2002; 39(6):795-802. DOI: 10.1097/00005344-200206000-00004. View

de Zeeuw D, Coll B, Andress D, Brennan J, Tang H, Houser M . The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014; 25(5):1083-93. PMC: 4005314. DOI: 10.1681/ASN.2013080830. View

Stavros F, Kramer W, Wilkins M . The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2010; 69(1):23-6. PMC: 2805874. DOI: 10.1111/j.1365-2125.2009.03541.x. View

Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer H, Loeffler B . Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation. 2001; 104(8):864-9. DOI: 10.1161/hc3301.094742. View

Barton M, Haudenschild C, dUscio L, Shaw S, Munter K, Luscher T . Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998; 95(24):14367-72. PMC: 24379. DOI: 10.1073/pnas.95.24.14367. View

10.

Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C . Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008; 294(5):F1185-94. DOI: 10.1152/ajprenal.00442.2007. View

11.

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C . In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005; 166(5):1309-20. PMC: 1606387. DOI: 10.1016/S0002-9440(10)62350-4. View

12.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

13.

Gabbay E, Fraser J, McNeil K . Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2008; 3(6):887-900. PMC: 2350123. View

14.

OConnor C, Gattis W, Adams Jr K, Hasselblad V, Chandler B, Frey A . Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol. 2003; 41(9):1452-7. DOI: 10.1016/s0735-1097(03)00194-3. View

15.

Mceniery C, Qasem A, Schmitt M, Avolio A, Cockcroft J, Wilkinson I . Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol. 2003; 42(11):1975-81. DOI: 10.1016/j.jacc.2003.06.016. View

16.

Epstein B . Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother. 2008; 42(7):1060-9. DOI: 10.1345/aph.1L024. View

17.

Trachtman H, Nelson P, Adler S, Campbell K, Chaudhuri A, Derebail V . DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018; 29(11):2745-2754. PMC: 6218860. DOI: 10.1681/ASN.2018010091. View

18.

Denault A, Pearl R, Michler R, Rao V, Tsui S, Seitelberger R . Tezosentan and right ventricular failure in patients with pulmonary hypertension undergoing cardiac surgery: the TACTICS trial. J Cardiothorac Vasc Anesth. 2013; 27(6):1212-7. DOI: 10.1053/j.jvca.2013.01.023. View

19.

Lenoir O, Milon M, Virsolvy A, Henique C, Schmitt A, Masse J . Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol. 2014; 25(5):1050-62. PMC: 4005294. DOI: 10.1681/ASN.2013020195. View

20.

Kohan D, Barton M . Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014; 86(5):896-904. PMC: 4216619. DOI: 10.1038/ki.2014.143. View